Skip to content

Assessment for effect of blood glucose control by using the flash glucose monitoring system (FGMS) in adolescents with type 1 diabetes mellitus

Efficacy of flash glucose monitoring system(FGMS) in adolescents with type 1 diabetes mellitus

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONC-17012388
Enrollment
Unknown
Registered
1990-01-01
Start date
2017-08-17
Completion date
Unknown
Last updated
2017-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 diabetes mellitus

Interventions

Observation group:flash continuous glucose monitoring system, FCGMS

Sponsors

The First Affiliated Hospital of Henan University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 15 Years

Inclusion criteria

Inclusion criteria: 1. The subject has documented Type 1 Diabetes , as defined by the American Diabetes Association and World Health Organization for at least 1 year prior to study enrollment; 2. The subject used continuous glucose monitoring until 3 months or more before the study started; 3. Aged =14 years; 4. The subject has an HbA1c value =12% at time of screening visit; 5. The subject is willing to follow study instructions

Exclusion criteria

Exclusion criteria: 1. Concomitant diseases that influence metabolic control or other medical condition, which in the Investigator's opinion, may compromise patient safety; 2. Significant co-morbidity that, in the opinion of the investigators would preclude participation in the study; 3. Any significant diseases or conditions including psychiatric disorders and substance abuse that in the opinion of the investigator is likely to affect the subject's ability to complete the study or compromise patient's safety 4. Subject is taking or has taken oral or parenteral glucocorticoids within 1 month prior to screening, or plans to take oral or parenteral glucocorticoids within the planned study duration. Exceptions: Short term oral or parenteral glucocorticoids up to 7 days; 5. Subject has known allergy to medical grade adhesives; 6. Subject is participating in another study of a medical device or drug that could affect glucose measurements or glucose management or receipt of any investigational medical product within 1 month prior to screening; 7. Female subject of child-bearing potential who have a positive pregnancy test at screening, is pregnant, breast-feeding, or planning to become pregnant within the planned study duration or is not using adequate contraceptive methods; 8. Subject diagnosed with current eating disorder such as anorexia or bulimia; 9. Subject has a history of one or more episodes of Diabetes Keto-Acidosis requiring hospitalization within a month prior to screening; 10. Subject has unstable or rapidly progressive renal disease or is receiving dialysis; 11. Subject has active proliferating retinopathy. Subject has current or recent history of alcohol or drug abuse Subject has visual impairment or hearing loss, which in the Investigator's opinion, may compromise patient ability to perform study procedures safely Any disease or condition that may influence the HbA1C testing

Design outcomes

Primary

MeasureTime frame
Glycosylated Hemoglobin;

Secondary

MeasureTime frame
Target Blood Glucose Range (3.9-7.8 mmol / L) Percentage of time;Target Blood Glucose Range (3.9-7.8 mmol / L) Percentage of time;Higher than the target blood glucose range (> 7.8mmol / L) percentage of time;Low blood glucose (<3.9mmol / L) Percentage of time;Low blood glucose (<3.9mmol / L) Percentage of time;The number of hypoglycemia;Adverse event rate;mean amplitude of glycemic excursion,MAGE;Standard deviation of blood glucose;Diabetes treatment satisfaction score;Hypoglycemia awareness score (Clarke score);Child depression score (CBCL 4/16);

Countries

China

Contacts

Public ContactHongwei Jang

The First Affiliated Hospital of Henan University of Science and Technology

jhwdr6@163.com+86 13653880139

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026